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6 ABSTRACT: Antimicrobial resistance (AMR) is a serious
7 threat to public health globally, manifested by the frequent
8 emergence of multidrug resistant pathogens that render
9 current chemotherapy inadequate. Health organizations
10 worldwide have recognized the severity of this crisis and
11 implemented action plans to contain its adverse consequences
12 and prolong the utility of conventional antibiotics. Hence,
13 there is a pressing need for new classes of antibacterial agents
14 with novel modes of action. Quorum sensing (QS), a
15 communication system employed by bacterial populations to coordinate virulence gene expression, is a potential target that
16 has been intensively investigated over the past decade. This Perspective will focus on recent advances in targeting the three main
17 quorum sensing systems (las, rhl, and pqs) of a major opportunistic human pathogen, Pseudomonas aeruginosa, and will
18 speciﬁcally evaluate the medicinal chemistry strategies devised to develop QS inhibitors from a drug discovery perspective.
19 ■ INTRODUCTION
20 Antimicrobial resistance is a global threat that is imposing an
21 ever increasing burden on public health because of the rapid
22 selection of antibiotic resistance associated with the over- and
23 misuse of antibacterial reagents.1,2 The withdrawal of most
24 major pharmaceutical companies from antibiotic discovery and
25 their alternative focus on chronic, noncommunicable diseases
26 reﬂects the diﬃculties in developing novel antibacterial agents
27 and the enormous cost of bringing new therapeutics to the clinic.
28 In addition, the increasing complexity of the legislation imposed
29 by regulatory bodies and risks associated with antibacterial drug
30 discovery research has restricted further advances in this ﬁeld.3,4
31 Over the past 17 years, only four new classes of antibiotics have
32 been discovered with the majority of FDA-approved drugs being
f1 33 based on alterations to existing structures (Figure 1).4−6
34 The antibiotic crisis is associated with the appearance of
35 multidrug resistant pathogens, also known as “superbugs” that
36 are capable of surviving antibiotic treatment as in the case of the
37 so-called “ESKAPE” panel pathogens (Enterococcus faecium,
38 Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
39 baumannii, Pseudomonas aeruginosa, and Enterobacter species).7
40 According to the World Health Organization (WHO),
41 Pseudomonas aeruginosa represents one of the “critical priority
42 pathogens” that requires urgent attention because of its
43 multidrug resistance (MDR) to a broad spectrum of antibiotics
44 including carbapenems and third generation cephalosporins.8,9
45 P. aeruginosa is commonly responsible for lung, skin, eye, wound,
46 blood-borne, and urinary tract infections occurring in both
47 hospitals and the community.10,11 This Gram-negative
48 bacterium is a common cause of nosocomial infections and a
49 major pathogen in both cystic ﬁbrosis (CF) and immunocom-
50promised patients and those with burns, open fractures, or
51implanted medical devices such as catheters.12,13
52■ VIRULENCE OF P. aeruginosa
53The clinical signiﬁcance of P. aeruginosa arises from its ability to
54express a plethora of virulence factors that aid invasion of, and
55cause damage to, host tissues.14 Among these, ﬂagella and pili
56contribute to tissue surface adhesion as well as to tissue
57migration via swarming and twitching motility.15,16 P. aeruginosa
58also secretes multiple tissue degrading exoenzymes, exotoxins,
59and host defense-inactivating eﬀector proteins which play key
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Figure 1. FDA approved antibiotics for the period 2000−2017 (red)
and novel approved antibiotic classes with unprecedented chemical
structures and modes of action (green). Data are collected from U.S.
Food and Drug Administration (FDA) (www.fda.gov as of March 15,
2018).
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60 roles in virulence and survival.14,17 Furthermore, P. aeruginosa
61 produces multiple secondary metabolites including hydrogen
62 cyanide (HCN) and is able to interfere with host oxidative stress
63 responses via the redox reactive pigment pyocyanin.18 It also
64 scavenges essential nutrients such as iron from the host proteins
65 transferrin and lactoferrin via the siderophores pyoverdine and
66 pyochelin.14,19 During chronic infections, P. aeruginosa forms
67 bioﬁlms, communities of bacteria usually attached to a surface
68 and surrounded by an extracellular matrix composed of
69 exopolysaccharides, proteins, nucleic acids, and lipids. Bioﬁlms
70 are highly tolerant to antibiotics and the immune system.20
71 Consequently, this extensive secreted macromolecular and
72 secondary metabolite “toolbox” of virulence factors makes P.
73 aeruginosa a formidable opportunistic pathogen.
74 ■ P. aeruginosa AS A “SUPERBUG”
75 P. aeruginosa is highly resistant to antimicrobials due to intrinsic,
76 acquired, and evolved mechanisms. P. aeruginosa exhibits
77 intrinsic resistance to antibiotics because of the low permeability
78 of its outer membrane and the presence of at least 12 eﬄux
79 pumps which are able to expel various antibiotics including
80 cephalosporins, carbapenems, ﬂuoroquinolones, and amino-
81 glycosides.21 In addition, β-lactamase genes are frequently
82 chromosomally encoded making P. aeruginosa resistant to
83 penicillins and cephalosporins.22 Acquired resistance in P.
84 aeruginosa is mainly driven by horizontal gene transfer whereby
85 genes coding for speciﬁc resistance traits are transferred from
86 one bacterium to another. Acquired resistance can also be
87 induced through a mutational change, for example, in DNA
88 gyrase, resulting in lower aﬃnity for ﬂuoroquinolones.23 A third
89 mechanism for developing resistance is known as evolved
90 resistance, whereby P. aeruginosa responds to numerous stimuli,
91 for instance, subinhibitory concentrations of antibiotics,
92 nutrient deprivation, pH, and temperature dependence and
93 through the expression of genes which enhance speciﬁc activities
94 such as eﬄux pump mechanisms and/or those that modify cell
95 envelope composition.23 For these reasons, the eﬀectiveness of
96 molecules targeting P. aeruginosa infections can be signiﬁcantly
97 compromised by these bacterial defense mechanisms. There-
98 fore, it is important that knowledge of existing resistance
99 mechanisms is considered when introducing new molecular
100 scaﬀolds into the rational design of inhibitors of bacterial QS
101 regulatory pathways.
102 ■ QUORUM SENSING AS A DRUG DISCOVERY
103 TARGET
104 QS is a mechanism for cell to cell communication between
105 bacteria that relies on the production and sensing of diﬀusible
106 quorum sensing signal molecules (QSSMs) that are sometimes
107 referred to as autoinducers (AIs). Once a bacterial population
108 reaches a certain threshold that is reﬂected by the concentration
109 of QSSMs in the surrounding environment, the transcription of
110 multiple genes is synchronized enabling the population to
111 behave collectively. This diﬀusible signal-mediated regulation
112 controls a wide range of activities from swarming and swimming
113 motility, bioﬁlm maturation, virulence factor, and secondary
114 metabolite production as well as antibiotic resistance.24 In
115 recent years, attempts to develop new classes of antimicrobial
116 agents have included the targeting of speciﬁc virulence factors or
117 virulence regulatory mechanisms rather than cell viability with a
118 view to minimize the selective pressures that lead to the
119 emergence of resistance.25−27 One of these strategies is directed
120toward interference with QS-mediated signaling to disrupt
121bacterial communication in order to attenuate virulence such
122that the infecting bacteria can be cleared by the host defenses.
123Hence, the use of QS inhibitors (QSIs) that do not directly
124compromise bacterial viability should impose less selective
125pressure with respect to resistance than conventional anti-
126biotics.28 QS inhibitors (QSIs) alone may not be suﬃcient to
127eradicate infections especially in immunocompromised individ-
128uals but are likely to act synergistically in combination with
129growth inhibitory antibiotics. QSIs may however be very
130eﬀective as prophylactics. Since 2000, the number of QS
131publications has shown a signiﬁcant upward trajectory mostly
132with respect the underlying molecular biology with medicinal
133chemistry related papers and published patent applications
134 f2representing only a small percentage of the total (Figure 2).
135■ QUORUM SENSING SYSTEMS IN Pseudomonas
136aeruginosa
137P. aeruginosa possesses three major QS systems, las, rhl, and pqs
138that are interconnected and highly integrated, with each system
139being autoregulatory while also modulating the activities of the
140 f3others (Figure 3). The las system for example positively controls
141both rhl and pqs system genes that code for QSSM receptors
142(rhlR and pqsR) and synthase genes (rhlI and pqsH). However,
143while some target genes are speciﬁcally regulated by las and
144others by rhl, some require both of these QS systems for full
145activation.29 The las and rhl systems rely on two diﬀerentN-acyl-
146L-homoserine lactone (AHL) type signal molecules (Figure 3, 1,
1472). The third QS circuit, pqs, employs 2-alkyl-4-quinolones
148(Figure 3, 3, 2-heptyl-4-hydroxyquinoline (HHQ), or 4, 2-
149heptyl-3-hydroxy-4(1H)-quinolone (PQS)) as QSSMs. The
150pathogenicity of P. aeruginosa strains with mutations in the key
151QS genes from the las, rhl, or pqs systems is highly attenuated in
152experimental infection models making QS a putative target for
153novel antibacterial agents.30
154For each QS system, activation of the receptor protein (LasR,
155RhlR, and PqsR) by the cognate QS signal molecule activates
156expression of the biosynthetic genes setting up an autoinduction
157loop to generate more signal molecules while also being
158responsible for the up-regulation of diverse genes associated
159with virulence, secondarymetabolism, and bioﬁlm development.
160From a drug discovery point of view, the QS systems can be
161targeted at four main levels: signal biosynthesis, signal reception,
162signal sequestration, and signal degradation.28 This review will
163focus mainly on antagonism of QSSMbiosynthesis and response
164in P. aeruginosa.
Figure 2. Representation of the number of publications related to QS
for the period 2000−2017 as analyzed using the Sciﬁnder Scholar
search tool (https://sciﬁnder.cas.org, as of March 15, 2018).
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165 ■ INHIBITION OF THE las QUORUM SENSING
166 SYSTEM
167 The las system in P. aeruginosa employs N-(3-oxododecanoyl)-
168 L-homoserine lactone (3OC12-HSL) as the cognate QSSM that,
169 upon binding the LuxR type transcriptional regulator LasR,
170 activates the expression of multiple genes. These include lasI
171 which codes for the 3OC12-HSL synthase as well as numerous
172 virulence factor genes (e.g., the elastases LasA and LasB, alkaline
173 protease, and exotoxin A) required for bioﬁlm development and
174 the rhl and pqs systems.20 Recent work has conﬁrmed that
175 pharmacological antagonism of the LasR receptor induces and
176 stabilizes conformational changes that prevent the complex
177 (LasR−antagonist) from binding to DNA so preventing
178 transcription of the target genes.31
179 ■ LasR INHIBITORS
180 LasR has attracted attention as a drug discovery target driven by
181 its position in the P. aeruginosa QS hierarchy. There is a
182 considerable amount of literature describing inhibitors for LasR
183 from the past 15 years, and these can be classiﬁed into four
184 categories: AHL-like antagonists, non-AHL-like antagonists,
185covalent binders, and natural-product-based inhibitors. It is also
186noteworthy that several assays for evaluating LasR inhibition
187have been described. These are mostly bacterial cell-based
188employing transcriptional fusions to LasR target gene promoters
189coupled to reporter genes providing bioluminescent or
190ﬂuorescent readouts.32,33 However, these assays have not been
191standardized and employ diﬀerent homologous (P. aeruginosa)
192or heterologous (E. coli) host strains making direct comparisons
193of inhibitor potencies between studies challenging.
194■ AHL-LIKE INHIBITORS
195Inhibitors with Modiﬁed Tail Structures. One of the
196earliest attempts to modify 3OC12-HSL was through the
197introduction of a sulfur containing tail which had variable eﬀects
198on LasR antagonism depending on chain length and the
199 f4oxidation state of the sulfur, with the best inhibitor 5 (Figure 4)
200displaying 50% LasR inhibition at 6 μM using an E. coli reporter
201strain.34 A recent patent described a sulfur-based tail 6 with IC50
202of 5.2 μM in a P. aeruginosa reporter strain.35 Another tail group
203modiﬁcation was introduced by Geske et al., who shortened the
204aliphatic chain and incorporated an aromatic end group (7 and
2058). Both compounds showed inhibition in a P. aeruginosa
Figure 3. Schematic diagram of the interconnected las, rhl, and pqs quorum sensing systems in P. aeruginosa. Green arrows and red blocked lines
indicate up- or down-regulation, respectively. Oval shapes represent various proteins, color coded circle shapes represent QSSMs, and large colored
arrows represent genes. Thin gray arrows represent protein expression, and thin blue arrows indicate QSSMs biosynthesis.
Figure 4. LasR inhibitors: AHL analogs with modiﬁed tail structures.
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206 reporter strain with IC50 values of 16.1 and 14.8 μM,
207 respectively.36 In a later study, the same group of researchers
208 expanded the SAR of these inhibitors and submicromolar
209 antagonists were identiﬁed using an E. coli reporter strain (9,
210 1.72 μM; 10, 610 nM; 11, 250 nM; 12, 340 nM).37 Similar
211 structures have also been published as LasR antagonists with
212 IC50 values of 1 and 10 μM for 13 and 14, respectively.
38
213 Although Jadhav et al. focused on the structure−activity
214 relationship of 3OC12-HSL analogs as immune modulators, a
215 series of LasR antagonists was found bearing modiﬁcations of
216 the hydrophobic tail region. The compounds were screened
217using a native P. aeruginosa reporter assay at 100 μM ligand
218concentration to reveal that 15 and 16 had reduced the activity
219of LasR to less than 6%.39 Triazole-derived tail structures were
220designed by Stacy et al. with various linker lengths from the
221headgroup, and the compounds were assessed using an E. coli
222LasR reporter assay to identify three LasR inhibitors with low
223micromolar IC50 (17, 3.27 μM; 18, 4.03 μM; 19, 2.64 μM).
40
224Modiﬁed Head Structures. Suga et al. published a series of
225compounds with modiﬁcations to the headgroup with various
226saturated and aromatic ring replacements preserving the tail
227structure which resulted in a number of agonists and antagonists
Figure 5. Structures of LasR inhibitors: AHL analogs with modiﬁed head structures.
Figure 6. Structures of non-native LasR inhibitors with non-AHL-like cores.
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228 with little structural diversity. One of the highlighted agonists in
f5 229 their work was compound 20 (Figure 5) which is based on 2-
230 aminocyclohexanol. Interestingly, the keto derivative 21 was
231 shown to be a weak antagonist at ligand concentrations of 50
232 μM. Replacing the saturated ring with an aromatic ring provided
233 antagonist 22 that exhibited reduced activity of LasR in PAO-
234 JP2 lasI-gfp, a lasI rhlI double mutant transformed with a
235 plasmid containing the lasI promoter fused to green ﬂuorescent
236 protein gene (gfp). Possible RhlR antagonism in the reporter
237 screens was also noted at concentrations of 10 μM or greater.
238 However, these results did not translate into virulence factor
239 attenuation with respect to pyocyanin or bioﬁlm reduction.41,42
240 The latter observation could be interpreted by the recent ﬁnding
241 of Moore et al. that 20 is actually a partial agonist and had no
242 antagonistic activity.43 Compound 23, containing a p-methox-
243 yphenyl group, exhibited inhibitory activity on pyocyanin and
244 elastase production with no evidence of reporter strain
245 inhibition.44 Modiﬁcations of the headgroup by Mclnnis et al.
246 were shown to be detrimental for activity with a phenyl group 24
247 being the best replacement among the published compounds.
248 Nevertheless, it had relatively weak activity when tested in a P.
249 aeruginosa reporter compared with E. coli.45 Park et al. designed a
250 series of compounds with a pyrone headgroup and aliphatic tail
251 that were validated using a bioﬁlm assay to conclude that 25 had
252 the strongest eﬀect particularly at 100 μM ligand concentration.
253 Even though the study presented some molecular docking data
254 on 25 binding to LasR, no experiments were performed to
255 validate this in silico modeling.46
256 ■ NON-AHL-LIKE STRUCTURES
257 The design of LasR inhibitors has also focused on addressing the
258 chemical and enzymatic stabilities associated with the original
259 lactone-based structure. The AHL lactone ring under alkaline
260 conditions undergoes a ring opening reaction to the
261 corresponding γ-hydroxycarboxylate.47 Further, the AHL
262 structure is also prone to enzymatic degradation by lactonases
263 and amino acylases which render these QSSMs inactive.48
264 In a search for non-AHL-like LasR inhibitors, Hentzer et al.
f6 265 disclosed a halogenated furanone 26 (Figure 6), which is a
266 synthetic analog of a furanone-derived natural product isolated
267 from the marine alga Delisia pulchra.49 Compound 26 showed a
268 dose-dependent inhibition of virulence and the development of
269 antibiotic resistant bioﬁlms. Transcriptomic proﬁling after
270 treatment of P. aeruginosa with 26 resulted in the repression of
271 diverse genes controlled by AHL-dependent QS. Most
272 importantly, 26 at a dose of 0.7 mg/kg had signiﬁcant eﬃcacy
273 in treating P. aeruginosa lung infections in a mouse infection
274 model.50,51 The mechanism of action of 26 however has not
275 been elucidated. The compound is toxic at concentrations of
276 ≥100 μM, and although surface enhanced Raman scattering
277 showed signal-speciﬁc structural changes in LasR upon ligand
278 binding, Moore et al. were unable to demonstrate inhibition of
279 LasR activity at subgrowth inhibitory concentrations in the lasR
280 bioreporter PAO-JP2 lasI-gfp.43
281 An ultrahigh throughput screen (UHTS) was performed on a
282 library of 200 000 compounds byMüh et al. using a P. aeruginosa
283 ﬂuorescently tagged reporter strain which gave two LasR
284 antagonists 27 and 28 with IC50 values of 30 nM and 10 μM,
285 respectively. The inhibition of LasR correlated with reduced
286 elastase and pyocyanin production. It is noteworthy that the
287 hydrophobic tail is still preserved to a certain extent in these two
288 molecules.52 Moreover, the screen also identiﬁed a LasR
289 inhibitor 29 with a low potency (IC50 = 50 μM). Similar
290compounds to 29 have been shown to be activators of the
291receptor, and cocrystal structures with LasR have been
292obtained.52,53 Borlee et al. screened a synthetic compound
293library of 16 000 compounds using a recombinant lasR
294expressing Pseudomonas putida for both agonists and antago-
295nists. LasR inhibitors with a thiocarbamate functionality (30 and
29631) were their most active hits showing antagonism of 50−60%
297of 3OC12-HSL (50 nM) at a concentration of 20 μM.54 Yoon et
298al. described a furanone-based series that was tested in an E. coli-
299based LasR reporter strain to demonstrate that compound 32
300was the most potent analog which also impacted on bioﬁlm
301formation. However, concentration and dose response curves
302were lacking.55 Biswas et al. proposed an indole derivative 33 as a
303replacement for the lactone, but their data suggest weak
304inhibition (65%) at concentration of 250 μM,56 while Nizalapur
305et al. designed a new compound containing a glycine ethyl ester
306branch 34which inhibited 3OC12-HSL-dependent activation of
307LasR in the P. aeruginosaMH602 reporter moderately by 48% at
308250 μM although there was minimal eﬀect on pyocyanin
309production.57 However, 34 was identiﬁed as a pan-assay
310interfering compound (PAIN) and hence may have given a
311false positive result.58 The glyxoamide-based macrocycle 35
312exhibited inhibitory activity of the bioreporter strain P.
313aeruginosa PAO1 MH64 and bioﬁlm formation at 250 μM.59
314Nielsen et al. performed a structure-based virtual screening on
315known LasR agonists on QS in P. aeruginosa using a library of
316approved drugs and natural products followed by in vitro
317assessment of the eﬀects of three candidates: salicylic acid 36,
318nifuroxazide 37, and chlorzoxazone 38. The results indicated
319that these three drugs can variably inhibit the three quorum
320sensing systems (pqs, las, rhl) and reduce bioﬁlm biomass at
321submillimolar concentrations.60 Another example of the virtual
322screening of a compound library was accomplished by Yang-Yi
323Tan et al., who concluded that 39 was a LasR antagonist (IC50 =
3240.64 μM) and signiﬁcantly reduced elastase production and
325bioﬁlm formation. However, 39 demonstrated multiple eﬀects
326on both the rhl and pqs QS systems.61 Utilization of computer-
327aided virtual screening to assist the identiﬁcation of new
328compounds was carried out by Skovstrup et al. and led to the
329discovery of a novel LasR inhibitor scaﬀold. The hits were
330evaluated using a P. aeruginosa bioreporter, and 40was shown to
331have an IC50 of 9 μM.
62 In another report, compounds
332containing a nonsymmetrical azine core were found to have an
333inhibitory activity on LasR in the reporter assay. Speciﬁcally, 41
334and 42 showed a dose-dependent response and bioﬁlm
335disruption at concentrations lower than 50 μM.63 Reilly et al.
336designed a hybrid compound 43 with an IC50 (4.8 μM) in an E.
337coli lasR reporter.64
338A recent patent described the N-thioacyl homoserine lactone
33944 as a las quorum sensing inhibitor with extended eﬀects on pqs
340and rhl at subinhibitory concentrations; however, the concen-
341tration used was not stated.65 Another patent reported that the
342pyrrolidin-2-ol derivative 45 inhibited both LasR and RhlR at
343concentrations around 400 μM without aﬀecting growth.66
344■ COVALENT BINDERS AS INHIBITORS FOR LasR
345Amara et al. developed a series of covalent antagonists with an
346electrophilic warhead, such as isothiocyanate, that is able to form
347a covalent bond with cysteine (Cys79) within the LasR ligand
348 f7binding site. The study focused on 46 (Figure 7) as it is a
349covalent binder with an IC50 of 134 μM in the P. aeruginosa
350reporter strain PAO-JP2 lasI-gfp. Bioﬁlm and pyocyanin
351production were also reduced at a 50 μM concentration.67
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352 In a follow-on study, 46 was reﬁned by the introduction of an
353 electronegative halogen at the β-position to increase the
354 electrophilicity of the isothiocyanate. Compound 47 was
355 thoroughly investigated for its binding to LasR Cys79, used in
356 an ex vivo human wound infection model and in a
357 Caenorhabditis elegans survival model where it protected the
358 worms from P. aeruginosa infections.68 Nevertheless, these
359 results have been recently contradicted by Moore et al., who
360 reported that 46 is a LasR agonist that induces LasB elastase
361 production.43 O’Brien et al. developed the irreversible binder 48
362 based on 29 with substitution of 2-chlorobenzoate by a
363 maleimide linker that was proposed to form a covalent bond
364 with Cys79. In an E. coli based reporter assay, 48 showed a
365 concentration-dependent inhibition with an IC50 of 4.8 μM and
366 was able to reduce pyocyanin production and bioﬁlm formation
367 in P. aeruginosa.69
368 ■ LasI INHIBITORS
369 LasI, the 3OC12-HSL synthase, has received less attention as a
370 target for disrupting the las-dependent QS. There appears to be
f8 371 only one report describing 49 (Figure 8) as a LasI inhibitor
372 (∼40% inhibition at 20 μM) in a heterologous E. coli-based
373 reporter strain causing a signiﬁcant reduction in bioﬁlm and
374 swarming motility. A microarray-based transcriptomic assay
375 revealed that lasI along with the pqsABCDE genes were down-
376 regulated after treatment with 49 compared to the untreated
377 cells, a result that would be expected given that LasR/3OC12-
378 HSL is involved in regulating both AHL and AQ biosynthesis in
379 P. aeruginosa (Figure 3).70
380 ■ INHIBITION OF THE rhl QUORUM SENSING
381 SYSTEM
382 The P. aeruginosa rhl system employs 2 N-butanoyl-L-
383 homoserine lactone (C4-HSL) and is responsible for the
384 expression of multiple virulence factors including rhamnolipids,
385 HCN, swarming motility and contributes to bioﬁlm maturation.
386 The expression of the rhl system is controlled by the las system
387 as the LasR/3OC12-HSL complex activates the transcription of
388 both rhlR and rhlI leading to more C4-HSL and the activation of
389 a wide range of RhlR/C4-HSL controlled genes. The rhl QS
390 system has received less attention compared with the las system
391 as most published work has focused on the latter probably due to
392 its location at the top of the P. aeruginosaQS hierarchy. Hence it
393 remains unclear as to whether RhlI and RhlR both represent a
394valid drug discovery target especially since a rhlI mutant in
395contrast to a rhlR mutant retains full virulence in a mouse
396infection model.71
397 f9The RhlR modulator 50 (Figure 9) was reported to act as an
398antagonist in the presence of C4-HSL and an agonist in its
399absence. 50 reduced pyocyanin production (IC50 = 8 μM),
400inhibited bioﬁlm formation, and enhanced C. elegans survival
401during a P. aeruginosa PA14 infection at 50 μM ligand
402concentration.72,73 However, a subsequent study, described 50
403as an agonist for RhlR, inhibiting pyocyanin production through
404down-regulation of the pqs system.74 Furthermore, 52 and 53
405were identiﬁed as RhlR agonists with EC50 values of 4.5 and 7.2
406μM in P. aeruginosa PAO-JP2 lasI-gfp reporter, respectively,
407signiﬁcantly reducing pyocyanin but not rhamnolipid produc-
408tion. It is noteworthy that these compounds appeared in a recent
409patent along with other analogs with the thiolactone head-
410group.75 The study concluded that for an RhlR modulator to
411function as an antivirulence agent, it is required to be an agonist
412rather than antagonist since it reduces pyocyanin production
413through pqs down-regulation.74,76 However, in such cases RhlR
414activation would lead to overproduction of rhamnolipids, a
415virulence factor involved in swarming, bioﬁlm maturation and
416detachment, and early inﬁltration of P. aeruginosa into human
417airway epithelia.77−79 Hence, RhlR requires further investigation
418and evaluation as antiquorum sensing target before considering
419it for any further medicinal chemistry optimization.
420■ NATURAL PRODUCTS
421There is considerable body of literature describing various
422natural products that interfere with P. aeruginosaQS particularly
423 t1the las and rhl systems. These eﬀorts are summarized in Table 1.
424■ PERSPECTIVE VIEW
425The lasQS system has been the most intensively investigated as
426an antivirulence drug target. Despite the numerous attempts to
427target signal reception (LasR) or signal synthesis (LasI), most
428inhibitors lack the lead-like properties required and failed to
429proceed to preclinical development due to one or more of the
430following drawbacks: (i) presence of hydrolytically and/or
431metabolically labile groups such as lactone/thiolactone or
432reactive species (i.e., isothiocyanate); (ii) unsurmountable
433physiochemical properties (e.g., high lipophilicity and/or
434molecular weight); (iii) weak potency and ambiguity of
435antivirulence proﬁles and eﬃcacy toward P. aeruginosa clinical
436isolates; (iv) lack of uniformity and standardization of
437methodology governing the assessment of the compounds,
438e.g., use of heterologous E. coli reporters. It should also be noted
439that lasR mutants frequently arise in chronic human P.
440aeruginosa infections.92 Nevertheless, the knowledge gained,
441along with the availability of crystal structures for LasR and LasI,
442should facilitate the future discovery and evaluation of more
443drug-like molecules. In addition, the administration route and
444indications for such inhibitors plays a major role in
Figure 7. Structures of LasR covalent binders.
Figure 8. Structure of a LasI inhibitor.
Figure 9. Structures of RhlR modulators.
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445 physiochemical property criteria deﬁnition; for instance,
446 transdermal treatment (i.e., for wound infections) will require
447 diﬀerent compound properties to those desirable for oral
448 administration.
93 With respect to rhl inhibition, it is not yet clear
449 whether antagonizing this system alone would yield therapeutic
450 beneﬁts. Moreover, the lack of structural information for RhlR
451and RhlI makes compound design more diﬃcult. Therefore, rhl
452requires further validation as a target.
453■ THE PSEUDOMONAS QUINOLONE SYSTEM (pqs)
454The P. aeruginosa pqs QS system relies on 2-alkyl-4-quinolone
455signal molecules rather than AHLs that interact with their
Table 1. Summary of Natural Product with P. aeruginosa QS Quenching Activities
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456 cognate receptor PqsR (also known as MvfR), a LysR family
457 transcriptional regulator that characteristically consists of an N-
458 terminal DNA-binding domain and a C-terminal ligand binding
f10 459 domain (Figure 3 and Figure 10). P. aeruginosa produces a
460 diverse range of over 50 AQ molecules of three main classes, 2-
461 alkyl-4-hydroxyquinolines, 2-alkyl-3-hydroxy-4-quinolones, and
462 2-alkyl-4-hydroxyquinoline-N-oxides including HHQ 3 (2-
463 heptyl-4-hydroxyquinolone), and the Pseudomonas quinolone
464 signal 4 (PQS) (2-heptyl-3-hydroxy-4(1H)-quinolone). PQS/
465 HHQ and their C-9 congeners are all able to activate PqsR. In
466 contrast to HHQ, PQS is an iron chelator and regulates the
467 expression of genes involved in the iron-starvation response and
468 virulence factor production via both PqsR-dependent and PqsR-
469 independent pathways.94,95 AQ biosynthesis is achieved via the
470 condensation of 70 and β-keto fatty acids mediated by the
471 heterodimeric enzyme PqsBC to aﬀord HHQ which can be
472 hydroxylated at the 3-position via PqsH to yield PQS.96,97 The
473 Co-A derivative of 70 is a product of the PqsA and PqsD
474 reactions starting from anthranilic acid 67. PQS and HHQ are
475 both able to interact with PqsR to form a PqsR/AQ protein
476 complex which in turn binds to the pqsA promoter leading to
477 further activation of the pqsABCDEphnAB operon hence
478triggering the autoinduction response characteristic of most
479QS systems.24,95 Recent studies have revealed that although
480PqsE is a thioesterase that contributes to AQ biosynthesis, the
481mechanism by which PqsE controls a subset of virulence factors
482including pyocyanin is still not understood.98,99 Interestingly,
483the pathogenicity of a P. aeruginosa pqsEmutant in contrast to a
484pqsA mutant was not attenuated in a mouse wound infection
485model. However, pqsE alone in the absence of AQ production
486can restore the virulence of a pqsA mutant.99,100
487The AQ system is linked with las and rhl QS as LasR
488(positively) and RhlR (negatively) regulate PqsR through
489binding to its promoter.101 Moreover, pqsH is positively
490regulated by LasR/3OC12-HSL which increases the abundance
491of PQS.102 The pqs system plays a major role in the virulence of
492P. aeruginosa as demonstrated by the attenuation of pqsA and
493pqsR mutants in murine infection models.99,103 In contrast to
494LasR/3OC12-HSL and RhlR/C4-HSL that bind to the
495promoters of multiple target genes, transcriptome experiments
496suggest that PqsR has only a single target promoter, that of
497pqsA.95 However, using ChIPseq, Maura et al. suggested that
498PqsR bound to 35 locations on the P. aeruginosa chromosome,
499although only 22% of these were to promoter regions.104Most of
Figure 10. Biosynthesis of alkylquinolones starting from activated anthranilic acid and mediated via PqsA, PqsBC, PqsD, and PqsE to generate HHQ
which is converted to PQS via PqsH. Non-AQ side products of this route are highlighted in red.
Figure 11. Structures of various PqsR antagonists.
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500 the binding sites were located inside a gene or overlapping
501 several genes, and hence their functionality as PqsR binding sites
502 remains to be validated.104
503 ■ INHIBITION OF pqs QUORUM SENSING IN P.
504 aeruginosa
505 Inhibition of Signal Reception by PqsR. Lu et al.
506 discovered a PqsR antagonist based on HHQ by introducing
507 modiﬁcations to the benzene moiety of the quinolone ring and
508 the aliphatic side chain. The highest potencies, as demonstrated
509 using a recombinant E. coli transcriptional reporter, were
510 achieved upon the introduction of a strong electron withdrawing
f11 511 group (Figure 11; 73, IC50 = 51 nM; 74, IC50 = 54 nM) at the 6-
512 position of the HHQ quinoline ring. Despite the fact that these
513 compounds showed good potency using the E. coli reporter, in P.
514 aeruginosa, only a modest reduction in pyocyanin was noted and
515 they failed to reduce elastase, rhamnolipids, or AQ levels.105,106
516 When 73 and 74 were further tested in P. aeruginosa, it became
517 clear that PqsH-mediated the oxidation at the 3-position of the
518 quinoline ring of these inhibitors converting them to potent
519 agonists. This eﬀect was not observed for compound 75 (IC50 =
520 35 nM, E. coli reporter, IC50 = 4 μM, P. aeruginosa reporter)
521 where a blocking group (CONH2) was introduced at the 3-
522 position to preserve the antagonistic activity in P. aerugino-
523 sa.107−109 Klein et al. reported another series of weak PqsR
524 inhibitors derived from N-hydroxybenzamides with modiﬁca-
525 tion at the para-position. Only modest activity against PqsR was
526 attained with 76 (IC50 in E. coli of 12.5 μM vs IC50 in P.
527 aeruginosa of 23.6 μM) which weakly aﬀected pyocyanin at IC50
528 concentrations.110 In a follow-up study, the carboxamide group
529 was replaced by a 1,3,4-oxadiazole moiety to provide 77 with
530 similar antagonist activity to 76 along with marginal activity on
531 pyocyanin and AQ production.111
532 In a similar eﬀort, the same group published a series of weak
533 PqsR antagonists based on a triazole scaﬀold (78, IC50 = 26 μM)
534 in a pursuit of dual PqsR/PqsD inhibitors. Compound 79, the
535 ﬁrst PqsR inhibitor with low micromolar potency in P.
536 aeruginosa, was discovered by Ilangovan et al. based on a
537 quinazolinone headgroup with a hydrazide at the 3-position. 79
538displayed a clear eﬀect on pyocyanin production, AQ synthesis,
539and bioﬁlm formation.112 Shortly after this study, Starkey et al.
540reported a PqsR antagonist 80 with submicromolar potency and
541a substantial eﬀect on virulence factors at concentrations of >1
542μM. In addition, 80 enhanced the eﬀect of tobramycin in
543clearing P. aeruginosa PA14 bioﬁlms. Moreover, this inhibitor
544potentiated the eﬀect of ciproﬂoxacin, reduced persistence, and
545increased postinfection survival rates in burn and lung infection
546models in mice.113,114 Spero Therapeutics published a patent for
547aryloxyacetoindoles as PqsR inhibitors detailing an extensive
548SAR. One of the optimal compounds 81 demonstrated
549submicromolar potency (50−250 nM) and around 50%
550reduction of AQs in an in vivo acute thigh infection model in
551mice after oral administration with 4 doses of 200 mg/kg
552postinfection.115 No further development of these inhibitors has
553been reported.
554■ STRUCTURAL INSIGHTSOF PqsR LIGANDBINDING
555DOMAIN
556To date, there is no report describing the crystal structure for the
557full length PqsR protein; however, the truncated co-inducer
558binding domain of PqsR (PqsRcbd) has been described in
559literature.112,116−118 Ilangovan et al. reported the ﬁrst crystal
560structure of PqsRcbd bound to a natural agonist (2-non-
561ylquinolin-4(1H)-one, NHQ; PDB code 4JVD) to show that
562the PqsR ligand binding site consists of two subdomains: pocket
563A which accommodates the co-inducer quinolone ring and
564pocket B where the aliphatic chain resides supported by
565hydrophobic interactions with Tyr 258, Ile189, Ile186, and
566 f12Val170 (Figure 12). The same group also described the cocrystal
567structure of PqsRCBD with the quinazolinone-derived inhibitor
56879 (PDB code 4JVI) which induced a subtle conformational
569change at the level of Thr265 in pocket A to accommodate the
570chlorine substituent at the 7-position. The binding of 79 also
571featured a hydrogen bond between the hydrazide group and the
572side chain of Leu207.112 Kitao et al. recently reported the crystal
573structure of 80 (PDB code 6B8A, Figure 12) which adopted a
574similar binding mode to 79 with the benzimidazole ring residing
575in place of quinazolinone and the thioacetamide linker making a
Figure 12. Overlay poses of the cocrystal structures of PqsR ligand binding domain with a natural agonist NHQ (PDB code 4JVD, green),
quinazolinone based antagonist 79 (PDB code 4JVI, blue), and thioacetamide based antagonist 80 (PDB code 6B8A, pink). Figure 12A highlights the
hydrophobic residues surrounding pocket B. Figure 12B shows the binding pose of heterocyclic headgroup residing in pocket A. The poses were
generated using Maestro, Schrödinger, LLC, New York, NY (2018).
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576 hydrogen bond to Gln194. It is noteworthy that the bulky
577 phenoxyphenyl group occupied the cigar shaped hydrophobic
578 pocket B and induced the reorientation of Leu183 and Ile186
579 residues.118
580 ■ INHIBITION OF AQ BIOSYNTHESIS
581 Inhibitors of PqsA. PqsA, a CoA-ligase enzyme, is the ﬁrst
582 enzyme in the AQ biosynthetic pathway responsible for the
583 conversion of anthranilic acid 67 into anthraniloyl-CoA 68
584 mediated via adenylation to give 82 followed by a thioester-
f13 585 iﬁcation (Figure 13).119 PqsA represents a valid antivirulence
586 target due its essential role in AQ biosynthesis. P. aeruginosa
587 pqsA mutants exhibit reduced bioﬁlm formation compared with
588 the isogenic wild type strains.100,120,121
589 Initial attempts to inhibit this enzyme were based on substrate
f14 590 analogs such as halogenated anthranilate derivatives (Figure 14,
591 83, 84, 85) which showed weak inhibition with millimolar
592 concentrations of the ligands being required to demonstrate an
593 eﬀect.119,122 Nevertheless, these PqsA inhibitors increased
594 survival rates in mice infected with P. aeruginosa and reduced
595 bacterial systemic dissemination.122 Ji et al. recently reported the
596 design of anthraniloyl-AMP analogs as PqsA inhibitors through
597 the replacement of the phosphate bridge by a sulfonamide based
598linker. Despite the high aﬃnity of 86 and 87 in the enzymatic
599assay (86, Ki = 88 nM; 87, Ki = 109 nM), the inhibitors only
600weakly reduced AQ and pyocyanin levels in P. aeruginosa most
601likely due to their limited bacterial cell permeability.123 The
602resolution of the PqsA ligand binding domain crystal structure
603by Witzgall et al. should aid the design of future enzyme
604inhibitors with improved potency and permeability.124
605Inhibitors of PqsD. PqsD is the second enzyme in the HHQ
606biosynthetic pathway and is responsible for the condensation of
607anthraniloyl-CoA 68 (Figure 10) with malonyl-CoA to produce
6082-aminobenzoylacetate-CoA 69.125 The ﬁrst weak PqsD
609 f15antagonists (Figure 15, 88, IC50 = 65 μM; 89, IC50 = 35 μM
610using in vitro enzymatic assays) were derived from inhibitors of
611FabH a structural and functional homolog of PqsD.126 These
612compounds were further optimized to low micromolar
613potencies (90, IC50 = 1.1 μM; 91, IC50 = 1.6 μM following
614the same assay) and were able to compete with anthraniloyl-
615CoA for the substrate pocket.127,128 Strikingly, this benzamide−
616benzoic acid scaﬀold was employed by the same group for the
617search of bacterial polymerase inhibitors (RNAP) as anti-
618bacterial agents.129 Although a follow-up study highlighted the
619areas of the molecules that contribute to selectivity against
620PqsD, this was only improved by 50-fold.128 Moreover, there
621was a lack of evidence for the eﬀect of these PqsD inhibitors on
622P. aeruginosa growth particularly given that RNAP inhibition was
623solely assessed in an E. coli based assay. Following a ligand-based
624approach, inhibitor 92 was identiﬁed with IC50 of 3.2 μM in
625PqsD functional assay (ITC:Kd = 13 μM). However, the in vitro
626eﬀect of 92 on bioﬁlm and AQ production was only achieved
627using high concentrations (250−500 μM).130 A follow-on paper
628described the SAR of 93 with little improvement in cellular
629activity.131 Urea-based PqsD inhibitors were also described by
630Sahner et al. with IC50 values of 0.5 μM and 0.14 μM for
631compounds 93 and 94, respectively.132,133 Once again, a similar
Figure 13. Formation of anthraniloyl-CoA mediated by PqsA through two consecutive half-reactions, ﬁrst is adenylation to form 82 followed by
thioesteriﬁcation to provide 68.
Figure 14. Structures of reported PqsA inhibitors.
Figure 15. Structures of reported PqsD inhibitors.
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632 scaﬀold was used by the same group to identify RNAP inhibitors
633 in E. coli which questions the selectivity of 93 and 94 against
634 PqsD and their eﬀect on bacterial growth.132 Catechol-derived
635 scaﬀold 95 was reported as a PqsD inhibitor based on the
636 structural similarity between PqsD and CHS2, a chalcone
637 synthase fromMedicago sativa. Despite the micromolar potency
638 in the enzymatic assay for 95 (IC50 = 7.9 μM), only a slight eﬀect
639 was obtained in cells at concentration of 0.25 mM.134 Moreover,
640 95was identiﬁed as PAINS structure and therefore could act as a
641 false positive in the enzymatic assay. A sulfonyl pyrimidine
642 scaﬀold was employed in the discovery of dual PqsD/PqsR
643 inhibitors by Thomann et al., who reported compound 96 with
644 selectivity against PqsD (IC50 = 1.7 μM) that caused a 60%
645 reduction in PA14 bioﬁlm at concentration of 100 μM.135
646 Interestingly, compound 97 which shares the same scaﬀold with
647 96 showed weak dual inhibition against both targets (PqsD, IC50
648 = 21 μM; PqsR IC50 = 15 μM) with eﬀects on pyocyanin and
649 bioﬁlm at high micromolar concentrations.135,136
650 Inhibitors of PqsE. PqsE is a thioesterase enzyme capable of
651 transforming the PqsD reaction product 69 (2-ABA-CoA) into
652 2-aminobenzoylacetate 70, the HHQ precursor. Although PqsE
653 mutants produce similar levels of HHQ to the wild type strain
654 they generate more DHQ arising from the intramolecular
655 cyclization of the PqsD product, 2-ABA-CoA.98,100 2-Amino-
656 acetophenone 72 is another metabolite obtained from this
657 pathway through the decarboxylation of 2-ABA-CoA 69. PqsE
658 therefore plays a central role in AQ biosynthesis and balances
659 the formation of AQs, 71 and 72 from 2-ABA-CoA with the
660 dead-end product, 71 and 72. However, the functions of PqsE
661 are not fully understood since the thioesterase activity does not
662 account for the AQ-independent activities of PqsE in regulating
663 virulence factors including pyocyanin, HCN, and rhamnopliids
664 in the absence of AQ production.95,100 The only attempt to
665 inhibit PqsE was achieved through fragment based drug
f16 666 discovery, and three fragments (Figure 16, 98, 99, 100) were
667 identiﬁed as inhibitors with submillimolar potencies with their
668 binding conﬁrmed by cocrystallization experiments and
669 isothermal calorimetry. Although these compounds attenuated
670 the thioesterase activity of PqsE, as demonstrated by the
671 accumulation of DHQ and 2-ABA, they failed to modulate
672 pyocyanin production.137 Therefore, the validity of PqsE as a
673 drug target requires further investigation particularly as another
674 broad spectrum thioesterase (TesB) in P. aeruginosamay be able
675 take over its biological function with respect to AQ biosyn-
676 thesis.98
677 Inhibitors of PqsBC. PqsBC is a heterodimeric β-keto acyl
678 synthase III enzyme responsible for the condensation of 2-ABA
679 70 and octanoyl CoA to form HHQ.97 It was reported that 2-
680 aminoacetophenone (2-AA) 72, a secondary metabolite from
681 the AQ biosynthesis pathway, was able to inhibit PqsBC with an
682 IC50 of 46 μM in a PqsBC-based biochemical assay
97 and
683 reduces virulence in an acute infection model in mice.138 Maura
f17 684 et al. reported the ﬁrst synthetic inhibitors for PqsBC (Figure 17,
685101) which are based on a benzimidazole scaﬀold, previously
686described for PqsR inhibitor 80. Through using LCMS/MS to
687quantify AQ synthesis intermediates, they found that some
688analogs were able to inhibit PqsBC as evidenced by a reduction
689in HHQ production concomitant with increased levels of 2-AA
690and DHQ. The EC50 values for 102 (dual PqsR and PqsBC) and
691103 (PqsBC)were determined in a PqsBC enzymatic assay to be
69213.4 μM and 12.5 μM, respectively. It is intriguing that minor
693structural changes to 94 (higher activity toward PqsR) enhanced
694the activity toward PqsBC. It has been shown that selective
695PqsBC inhibitors induced less tolerance in P. aeruginosa cells
696toward the β-lactam antibiotic meropenem compared to dual or
697selective PqsR inhibitors.139 Allegretta et al. re-evaluated
698previously published pqs inhibitors and their eﬀect on PqsBC
699inhibition and showed that compounds 104 and 105 are able to
700signiﬁcantly induce an increase in 2-AA and DHQ levels at
701concentrations of 10 μM and 250 μM.140 It is noteworthy that
702compound 104 was reported as a weak PqsD inhibitor in a
703previous study.131 However, the validity of PqsBC as
704antivirulence drug target remains doubtful as even though
705PqsBC inhibition leads to a reduction of AQ signal synthesis, it
706induces accumulation of 2-AA and DHQ, molecules that
707enhance the persistence of P. aeruginosa and promote chronic
708infections.138,140,141 Hence, PqsBC inhibitor combination
709therapy would be advisible with other pqs pathway inhibitors.
710■ GENERAL AND MULTITARGET pqs INHIBITORS
711In addition to the compounds listed above, there are other
712reports of pqs inhibitors with no speciﬁc, deﬁned targets. For
713instance, recent work described 4-aminoquinoline derived
714molecules as inhibitors for pqs signaling with a potency of ∼2
715 f18μM for compound 106 (Figure 18) against P. aeruginosa PA14.
716The study demonstrated the eﬀect of this class of inhibitors in a
717series of phenotypic assays including bioﬁlm formation in two
718diﬀerent laboratory strains of P. aeruginosa (PAO1-L, PA14).
719Molecular docking studies implicated PqsR as the plausible
720target, but this was not conﬁrmed experimentally.142 The 7-
721chloroquinoline scaﬀold was also presented in another study
722showing that 107 was able to disrupt bioﬁlm formation and
723pyocyanin production at a concentration of 138 μM through
724inhibition of PQS signaling (81%).143 Pyrrol derivative 108 was
725reported in a patent as a pqs inhibitor with IC50 values of 22 μM
726and 17 μM in strains PAO1-L and PA14, respectively. 108
727reduced pyocyanin and AQ biosynthesis without aﬀecting
728bacterial growth up to a concentration of 100 μM.144 Fong et al.
729reported a “pan” QS inhibitor 109 for P. aeruginosa with low-
730micromolar activity (IC50 of 0.56 μM for las, 3.49 μM for rhl, and
7315.63 μM for pqs using P. aeruginosa reporters) leading to the
732down-regulation of multiple virulence factors (pyocyanin,
733rhamnolipids, elastase). 109 also exhibited high clearance rate
734of bacteria post foreign body infections in mice.145
735■ PERSPECTIVE VIEW
736The pqs system in P. aeruginosa is crucial for the full virulence
737and persistence of this human pathogen as well as some of its
738immune modulatory eﬀects. Reports describing the occurrence
739of lasR mutations in clinical P. aeruginosa isolates from chronic
740infections such as those encountered in cystic ﬁbrosis lend
741further signiﬁcance to pqs signaling as a target for antipseudo-
742monal drugs. Now that themechanistic biochemical basis for pqs
743biosynthesis and signal transduction have been elucidated and
744complemented with an understanding of the structural basis for
Figure 16. Structures of reported PqsE inhibitors.
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745 its essential components including crystal structures for PqsR,
746 PqsA, PqsD, PqsBC, and PqsE, it is clear that certain elements of
747 the pqs system represent attractive drug discovery targets.
748 Indeed, inhibitors 80 and 81 have advanced in preclinical stages
749 and the available data provide a robust proof of concept for
750 targeting PqsR. PqsA, PqsD are emerging as additional new
751 targets that have yet to be fully explored. Despite the fact that the
752 PqsBC heterodimer is critical for AQ biosynthesis, its validity as
753 antivirulence targets remains to be elucidated. The lack of
754 attenuation of pqsEmutants in mouse infectionmodels indicates
755 that PqsE is unlikely to be a good target.
756■ RESISTANCE TO ANTIQUORUM SENSING AGENTS
757There is some evidence that QS mutants arise in bacterial
758populations speciﬁcally under conditions where QS is essential
759for bacterial growth but only where they continue to beneﬁt to
760from the metabolic activities of QS competent cells.
146 QSI
761resistance could fall into one of the following categories: (i)
762overexpression of QS signal receptor genes or a receptor
763homologue to overcome inhibition, (ii) point mutations in the
764receptor such that it becomes signal independent, and (iii)
765preference of one particular QS system over others.147
Figure 17. Structures of published PqsBC inhibitors.
Figure 18. Structures of reported general and multitarget pqs inhibitors.
Table 2. Summary of Preclinical QS Inhibitors in P. aeruginosa with Their Predicted Physicochemical Propertiesa
aThe asterisk (∗) indicates that these parameters were predicted using Instant JChem 18.8.0, 2018, ChemAxon (http://www.chemaxon.com).
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766 There are few reports describing the development of
767 resistance to QSIs in P. aeruginosa. For the furanone-derived
768 compound 27, the underlying resistance mechanism was solely
769 reasoned to the up-regulation of an eﬄux pump due to a
770 mutation in mexR and nalC regulatory genes.148,149 However, it
771 is noteworthy that the QSI concentration used for this study was
772 at least 25-fold higher than that previously reported for QS
773 inhibition by 26 in the original literature. At such elevated
774 concentrations, 26 is cytotoxic and growth inhibitory and so will
775 exert selective pressures on the bacteria to drive the evolution of
776 mutations that confer resistance.
777 Currently, the literature relating to QSI resistance is scarce
778 and limited to certain cases and speciﬁc growth conditions.
779 Further investigations of selection for QSI resistance in
780 conditions that mimic in vivo infections will be vital to establish
781 a sound platform for the future design and development of QSIs
782 with nanomolar potencies.
783 ■ CONCLUSION
784 Through reviewing the medicinal chemistry related QS
785 literature, it is clear that more eﬀort needs to be directed toward
786 the design of drug-like molecules with favorable physiochemical
787 properties. It becomes evident that the majority of the inhibitors
788 identiﬁed to date function as useful probes for mechanistic
789 studies rather than lead-like compounds for further drug
t2 790 development as summarized in Table 2.
791 In addition, the lack of methodological standardization in
792 assessing QSI candidates including the use of single laboratory-
793 adapted P. aeruginosa strains limits the broad validity of any
794 ﬁndings such that these may be distant from relevant clinical
795 infections and so constitute a major pitfall in this ﬁeld. Within
796 the P. aeruginosa QS circuitry, the pqs system holds promise for
797 prospective therapeutics particularly at the level of PqsR where
798 inhibitors with nanomolar potencies and lead-like properties
799 have already been developed. However, it is important to note
800 that QS inhibitors are most likely to be beneﬁcial as adjuvants for
801 conventional antibiotics rather than as standalone therapeutic
802 agents, although they may prove useful for prophylaxis.
803 Undoubtedly, polypharmacology through the concurrent use
804 of inhibitors for various targets/QS systems could also prove
805 highly beneﬁcial in combating multiantibiotic bacterial resist-
806 ance.
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823 then joined Prof. Caḿara, Dr. Stocks, and Prof.Williams groups to work
824 on multinational project (SENBIOTAR) for the discovery of new PqsR
825 antagonist as novel antipseudomonal agents. Along his work, he
826contributed to teaching and supervision of a number ofM.Sc. and Ph.D.
827research students.
828Paul Williams is currently Professor of Molecular Microbiology in the
829School of Life Sciences, Faculty of Medicine and Health Sciences,
830University of Nottingham, U.K. From 1996 to 2008 he was Director of
831the Institute of Infections & Immunity after which he became Head of
832the School of Molecular Medical Sciences, University of Nottingham.
833His research interests focus primarily on the regulation of gene
834expression in bacteria through cell−cell communication (quorum
835sensing) and the development of novel antibacterial agents and
836bacterial bioﬁlm resistant polymers. He has published over 300 research
837papers and reviews, has served on the Medical Research Council UK
838MRC Infection and Immunity board and the scientiﬁc advisory board
839of the EU Joint Programming Initiative in Antimicrobial Resistance and
840is a Wellcome Trust Senior Investigator.
841Michael J. Stockswas appointed as an Associate Professor inMedicinal
842Chemistry in 2012 within the School of Pharmacy at The University of
843Nottingham. He has over 20 years of industrial experience in drug
844discovery within AstraZeneca, and during his industrial career, he was
845both the lead scientist and project leader on multiple preclinical
846research projects as well as the synthetic medicinal chemistry lead of the
847AstraZeneca compound enhancement initiative. Since joining the
848School of Pharmacy in 2012, Michael has grown his research group and
849his research has focused on the medicinal chemistry design of
850compounds to study and modulate the function of biological targets.
851Miguel Ca ́mara is a Professor of Molecular Microbiology in the School
852of Life Sciences, University of Nottingham since 2009. He has 24 years
853of expertise studying molecular mechanisms of quorum sensing-based
854control of gene expression in bacteria with emphasis on bioﬁlms, the
855inﬂuence on the behavior of polymicrobial communities, and the
856interaction with mammalian hosts and eukaryotic organisms. He has
857also been working on the identiﬁcation of novel antimicrobial targets to
858treat detrimental bioﬁlms and coordinated several international
859antimicrobial programs mainly focused on quorum sensing inhibition
860as the main target. He has >120 research papers in peer reviewed
861journals and is co-director of the National Bioﬁlms Innovation Centre
862and a member of the UK Cystic Fibrosis Trust Strategic
863Implementation Board.
864■ ACKNOWLEDGMENTS
865This work was supported by the Medical Research Council
866(Grant MR/N020081/1) U.K. and the Biotechnology and
867Biological Sciences Research Council (Grant BB/R012415/1)
868U.K.
869■ ABBREVIATIONS USED
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871decanoyl)-L-homoserine lactone; AHL, acylhomoserine lactone;
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873quinolone; C4-HSL, N-butanoyl-L-homoserine lactone; FDA,
874U.S. Food and Drug Administration; HCN, hydrogen cyanide;
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877multidrug resistance; PQS, Pseudomonas quinolone signal; QS,
878quorum sensing; QSI, quorum sensing inhibitor; QSSM,
879quorum sensing signal molecule; QZN, quinazolinone; WHO,
880World Health Organisation.
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